News 2015 - Workgroup For The Liver

Go to content

Main menu:

News 2015


Update: 2015/10/20


Manuscript accepted!
Our manuscript entitled "Effects of oxaliplatin-based chemotherapy on liver function - An analysis of impact and functional recovery using the LiMAx test" has been accepted for publication in Langenbeck's Archives of Surgery.


!!!CONGRATULATIONS!!! Sabine Gebhardt, successfully defended her doctoral thesis
Her thesis is entiteled "Risk factors of metabolic disorders after liver transplantation: an analysis of data from fasted patients".
As major outcomes of her studies, Sabine showed that initial poor graft function is a risk factor for post orthotopic liver transplantation diabetes mellitus. Furthermore, in-depth analysis identified additional transplantation-related risk factors, like hypercholesterolemia, BMI and postoperative renal dysfunction.
Dr. Gebhardt, Congratulations and all the best for the upcoming challenges and future steps!!


Our workgroup contribution to the Viszeralmedizin 2015 congress
From the 16 th-19 th of September the Viszeralmedizin 2015 congress was held in Leipzig, Germany. The congress is a joint meeting of the German Society for Digestive and Metabolic Diseases ( DGVS ) and German society for general and visceral surgery (DGAV), bringing together Germany’s leading gastroenterologists and general and visceral surgeons.
Three members of group presented novel data on
1) Pre-operative  volumetric  and  functional  assessment allows prediction of post-operative liver function.
2)  Reduction of morbidities and mortality rates by implementing the LiMAx algorithm in pre-operative planning.
3) The influence of  postoperative bile leakage on liver regeneration.
4) The effects of oxaliplatin chemotherapy on dynamic liver function.


Annual LiMAx workshop held in Berlin

On September 11, 2015 the annual LiMAx workshop was held in Berlin. With contributions from LiMAx users from several German and international Liver centers, recent developments and new clinical areas of application were presented and future perspective discussed. The workshop is intended to foster an open dialogue between clinical users, scientists and technology developers to support continues improvement in diagnosis by the LiMAx test.

We thank all participants and speakers for sharing your experiences and look forward to next year's workshop!

If you are interested in dynamic liver function testing, more information is available on the Humedics webpage.
If you wish to attend future meetings or receive updates on the LiMAx test, feel free to contact


SPIEGEL Online reports about the LiMAx test
In a recent
article, the technical details, the diagnostic application and the future perspective of the LiMAx test to become a tool in routine diagnostic prior to liver surgery are presented.
To date, the LiMAx test is already used in several European University Hospitals to complement imaging-based diagnostics in preparation of liver surgeries. If you are interested to learn more about the test and its possible applications, contact Humedics.



Jan Bednarsch et al. investigated the liver function in patients receiving oxaliplatin chemotherapy. Chemotherapy-associated hepatotoxicity is a risk factor in patients undergoing partial liver resection and is associated with increased perioperative mortality and morbidity. Therefore, exact and reliable liver function assessment might improve liver surgery planning by a patient-specific optimization of the chemotherapy-free intervall prior to liver surgery. In two cases, the LiMAx (maximum liver function capacity) test appeared as sensitive tool to diagnose mild functional impairment after chemotherapy, while standard liver function tests still remained within normal ranges.

The article is entiteled "Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test - two case reports and a review of the literature." and published in BMC Res Notes. 2015;8:99.


Macej Malinowski et al. assessed factors influencing the pro-operative growth of the future liver remnant after portal vein embolization (PVE). As key results, we found that small initial future liver remnant size, longer time between PVE and liver surgery and the absence of recanalization in the embolized lobe to be associated with better post-PVE future liver remnant growth.
The original article entiteled
"Factors influencing hypertrophy of the left lateral liver lobe after portal vein embolization." has been published in Langenbeck's Archives of Surgery in February 2015 (400:237-46).


Back to content | Back to main menu